Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Multicenter-undersøgelse for at evaluere det kliniske resultat af PrimeTaper EV-implantat i enkelttandsrestaureringer

11. september 2026 opdateret af: Dentsply Sirona Implants and Consumables

En åben, prospektiv, multicenter-undersøgelse for at evaluere det kliniske resultat af PrimeTaper EV-implantat i ekstraktionsfatninger og helede kamme - en 5 års opfølgning

The purpose of this study is to evaluate the clinical outcome of implant survival of the PrimeTaper EV implant in single tooth restorations 1 year after permanent restoration.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

138

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Leuven, Belgien, B-3000
        • Catholic University of Leuven
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242-1010
        • University of Iowa
      • Apeldoorn, Holland, 7315CA
        • Dr.F.L.Guljé, De Mondhoek
      • Busto Arsizio, Italien, IT-21052
        • Studio Toia
      • Alzey, Tyskland, DE-55232
        • Dental practice Dr Mischa Krebs

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adult aged 18-75 years.
  • Willing and able to sign and date the informed consent form.
  • In need of an implant in position 16 to 26 or 36 to 46, and each subject can only receive one implant.
  • Deemed by the investigator as likely to present with an initially stable implant situation.
  • A stable occlusion, i.e. an opposing natural dentition, a crown, an implant-supported fixed or removable prosthesis, a partial removable prosthesis or a full denture.
  • An adjacent tooth (root with natural or artificial crown) or an implant-supported crown mesially and distally. Exemption: If the planned implant is in the first molar position, an edentulous space is accepted distally

Exclusion Criteria:

  • Not willing to participate in the clinical investigation or not able to understand the content of the clinical investigation.

  • Unlikely to be able to comply with clinical investigation procedures according to investigator's judgement.

  • Unable or unwilling to return for follow-up visits for a period of 5 years.

  • Known allergy or hypersensitivity to titanium and/or stainless steel.

  • Uncontrolled pathological process in the oral cavity, e.g. untreated rampant caries and uncontrolled periodontal disease.

  • Uncontrolled para-functional habits, e.g. bruxism.

  • Current need of any Guided Bone Regeneration (GBR) procedure in the planned implant area (gap filling at immediate placement and soft tissue grafting are allowed).

  • Systemic or local disease or condition that would compromise post-operative healing and/ or osseointegration.

  • Immunosuppression, use of corticosteroids, per-os or intravenous bisphosphonate use, or any other medication such as anti-resorptive therapy or monoclonal antibodies that could compromise post-operative healing and/or osseointegration.

  • Any other condition that would make the subject unsuitable for participation, including but not limited to;

    • History of radiation therapy in the head and neck region.
    • History of chemotherapy within 5 years prior to surgery.
    • Present alcohol and/or drug abuse.
    • Ongoing psychiatric illness.
    • Current smoking/use of tobacco, including e-cigarettes.
  • Any ongoing disease that would make the subject unsuitable for participation, including but not limited to;

    • Recent myocardial infarction (< 3 months*).
    • Recent cerebrovascular accident (< 3 months*).
    • Recent cardiac-valvular prosthesis placement (< 3 months*).
    • Hemorrhagic diathesis.
    • Severe liver dysfunction.
    • Known or suspected current malignancy.
    • Uncontrolled diabetes mellitus.
    • Florid infection.
  • Pregnant or breastfeeding females. (Pregnancy tests will be performed as per local requirements).

  • Previous enrolment in the present clinical investigation.

  • Involvement in the planning and conduct of the clinical investigation (applies to both Dentsply Sirona staff and the clinical investigation site).

  • Simultaneous participation in another clinical investigation, or participation in a clinical investigation during the last 6 months that may interfere with the present clinical investigation.

    • < 3 months is a strict exclusion criterion. After 3 month it is up to the investigator to judge whether the subject is considered suitable for participation or not.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Single tooth restorations

A single, open-label group with patients in need of single tooth restorations will receive PrimeTaper EV implant system with diameters 3.6, 4.2, 4.8, 5.4 mm, and lengths 6.5, 8, 9, 11, 13, 15 and 17 mm.

Tapered dental implant developed by Dentsply Sirona

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Implant Survival, i.e. Number of Implants in Place Counted Clinically, 1 Year After Permanent Restoration.
Tidsramme: One year post permanent restoration (anticipated average 3 months after implant placement).

Implant survival rate is a binary variable evaluated clinically, i.e. 'Yes' or 'No' where 'Yes' means that the implant is still in place and 'No' means that the implant is not in place. Any implant that has been removed or lost after implant placement visit will be considered a failure, whatever the reason for removal/loss.

One year post permanent restoration (anticipated average 3 months after implant placement).

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Implant Survival, i.e. Number of Implants in Place Counted Clinically, 2, 3, 4 and 5 Years After Permanent Restoration.
Tidsramme: 2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).

Implant survival rate is a binary variable evaluated clinically, i.e. 'Yes' or 'No' where 'Yes' means that the implant is still in place and 'No' means that the implant is not in place. Any implant that has been removed or lost after implant placement visit will be considered a failure, whatever the reason for removal/loss.

2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Change of Implant Stability Quotient Value (ISQ) Between Implant Placement and Permanent Restoration.
Tidsramme: From date of implant placement (anticipated average 1 month after inclusion) to date of permanent restoration (anticipated average 3 months after implant placement).

Implant stability will be evaluated through ISQ value using Resonance Frequency Analysis (RFA). The stability is presented as an ISQ value. The higher the ISQ value the higher the stability. Recorded as a numeric value (1-100).

From date of implant placement (anticipated average 1 month after inclusion) to date of permanent restoration (anticipated average 3 months after implant placement).
Maximum Insertion Torque Value for Each Implant at Implant Placement.
Tidsramme: At date of implant placement (anticipated average 1 month after inclusion).

Maximum insertion torque value (ITV), based on ITV curve, measured in Ncm.

At date of implant placement (anticipated average 1 month after inclusion).
Final Insertion Torque Value for Each Implant at Implant Placement.
Tidsramme: At date of implant placement (anticipated average 1 month after inclusion).

Final insertion torque value (ITV), based on ITV curve, measured in Ncm.

At date of implant placement (anticipated average 1 month after inclusion).
Investigator Questionnaire for Each Investigational Medical Device After Implant Placement.
Tidsramme: Immediately after implant placement (anticipated average 1 month after inclusion).

Numerical scale 1-10, where 1 = totally disagree with the statement, and 10 = totally agree with the statement. Statements to be evaluated by the surgeon: "The implant was guided into the prepared osteotomy", "The implant followed the prepared osteotomy", "The implant has a good primary stability", "The drilling protocol is easy to use", "The implant has efficient cutting properties". Each statement will be evaluated separately.

Immediately after implant placement (anticipated average 1 month after inclusion).
Implant Success, i.e., Number of Implants Documented as Successful at 1, 2, 3 and 5 Years After Permanent Restoration.
Tidsramme: 1, 2, 3 and 5 years post permanent restoration (anticipated average 3 months after implant placement).

Successful implants counted, i.e. 'Yes' or 'No'. An implant will be considered successful if all of the following criteria are fulfilled:

  1. Implant in place.
  2. Lack of evidence of peri-implant radiolucency in X-ray.
  3. Less than 1mm vertical bone loss during first year after loading with permanent restoration and 0,2mm annually thereafter.
  4. Absence of persistent and/or irreversible signs and symptoms such as pain, infections, neuropathies, paresthesia, or violation of the mandibular canal.
1, 2, 3 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Change of Marginal Bone Level up to 5 Years Post Permanent Restoration Compared to Permanent Restoration.
Tidsramme: At permanent restoration (anticipated average 3 months after implant placement) and 1, 2, 3 and 5 years post permanent restoration.

MBL changes determined from radiographs, expressed as the distance from the implant reference point to the most coronal bone-to-implant contact on the mesial and distal side of the implant. The average will be calculated and compared for each evaluation period.

At permanent restoration (anticipated average 3 months after implant placement) and 1, 2, 3 and 5 years post permanent restoration.
Change of Probing Pocket Depth (PPD) in mm Between Permanent Restoration, and 6 Months, 1, 2, 3, 4 and 5 Years After Permanent Restoration.
Tidsramme: At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.

Probing Pocket Depth (PPD) measured as the distance from the mucosal margin to the bottom of the probe-able pocket in mm.

At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.
Presence of Bleeding on Probing (BoP), at Permanent Restoration, and 6 Months, 1, 2, 3, 4 and 5 Years After Permanent Restoration.
Tidsramme: At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.

Bleeding on Probing (BoP) recorded as presence or absence of bleeding when probing to the bottom of the pocket.

At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.
Presence of Plaque at 6 Months, 1, 2, 3, 4 and 5 Years After Permanent Restoration.
Tidsramme: 6 months, 1, 2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).

Plaque recorded as presence or absence of plaque by visual inspection on four surfaces at each implant site.

6 months, 1, 2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Occurrence of Adverse Events, Adverse Device Effects, and Device Deficiencies During the Clinical Investigation.
Tidsramme: Up to 5 years after permanent restoration (anticipated average 3 months after implant placement).

Adverse Events, Adverse Device Effects, and Device Deficiencies spontaneously reported, and collection at each clinical investigation visit.

Up to 5 years after permanent restoration (anticipated average 3 months after implant placement).

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Andy Temmerman, Prof., KU Leuven

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. maj 2022

Primær færdiggørelse (Faktiske)

12. marts 2025

Studieafslutning (Anslået)

1. maj 2029

Datoer for studieregistrering

Først indsendt

16. marts 2022

Først indsendt, der opfyldte QC-kriterier

6. april 2022

Først opslået (Faktiske)

7. april 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • C-PT-21-001

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .